Abstract
Intravenous immunoglobulin (IVIg) is currently derived from a purified human plasma pool of more than 1000 healthy blood donors and contains IgG in supraphysiologic levels, including traces of other immunoglobulins. IVIg exerts a variety of immunomodulating activities and is currently used for the treatment of (1) primary and secondary immunodeficiency diseases, (2) autoimmune disorders, and (3) certain infectious diseases. The exact mechanisms responsible for the immunomodulating activity of IVIg are not yet completely understood and need to be further investigated. In times of targeted therapies by using biologicals, IVIg still plays an important role in the treatment of different skin diseases. There is accumulating evidence that IVIg is an effective and safe treatment for various skin diseases, and thus may lead to a significant reduction in adjunctive therapy with immunosuppressive agents. Randomized double-blind placebo-controlled trials have been published for dermatomyositis and pemphigus, and other dermatologic indications may follow. This chapter summarizes the currently available clinical experience with IVIg in the treatment of skin diseases. Wherever possible, a critical evaluation of IVIg efficacy and safety will be given for various indications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
